Results 121 to 130 of about 601,308 (135)

Ocriplasmin: a guide to its use in symptomatic vitreomacular adhesion

Drugs & Therapy Perspectives, 2014
Ocriplasmin (Jetrea®) is a stable, recombinant, truncated form of human serine protease plasmin that has proteolytic activity against the protein components of the vitreous and vitreoretinal interface, thereby facilitating vitreous liquefaction and separation of vitreous from the retina.
Gillian M. Keating, Yahiya Y. Syed, Sohita Dhillon   +2 more
openaire   +1 more source

SAFETY PROFILE OF OCRIPLASMIN FOR THE PHARMACOLOGIC TREATMENT OF SYMPTOMATIC VITREOMACULAR ADHESION/TRACTION

Retina, 2015
To report the safety of intravitreal ocriplasmin injection based on 2 Phase 3 clinical trials in patients with symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with full-thickness macular holes.Safety analyses were based on 2 completed Phase 3 studies assessing intravitreal ocriplasmin injection. Adverse events (AEs),
Kaiser, Peter K., Kampik, Anselm, Kuppermann, Baruch D., Girach, Aniz, RIZZO, STANISLAO, Sergott, Robert C.   +5 more
openaire   +2 more sources

SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION

Retina, 2015
After the recent approval of ocriplasmin by the Food and Drug Administration, postmarketing safety concerns have been raised by the vitreoretinal community. The American Society of Retina Specialists Therapeutic Surveillance Committee was commissioned to monitor postmarketing drug-related and device-related adverse events. The purpose of this report is
Paul, Hahn, Mina M, Chung, Harry W, Flynn, Suber S, Huang, Judy E, Kim, Tamer H, Mahmoud, Srinivas R, Sadda, Pravin U, Dugel   +7 more
openaire   +2 more sources

Full-Thickness Macular Hole and Symptomatic Vitreomacular Adhesion: Comparison of Visual Results in Patients Receiving Pars Plana Vitrectomy in One Eye and Ocriplasmin in the Fellow Eye

Journal of Vitreoretinal Diseases, 2019
Purpose: This article compares bilateral visual outcomes in patients receiving a vitrectomy in one eye for a full-thickness macular hole (FTMH) who also received ocriplasmin treatment in the fellow eye for symptomatic vitreomacular adhesion (VMA). Methods:
Arshad M Khanani, Joseph M Coney, Greggory M Gahn   +2 more
exaly   +2 more sources

[Research update of ocriplasmin for symptomatic vitreomacular adhesion].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 2015
Ocriplasmin is a recombinant truncated form of human serine protease plasmin with proteolytic activity to induce vitreous liquefaction and weaken vitreomacular adhesion, thereby facilitating posterior vitreous detachment and acting as a potential alternative to replace the more traumatic vitrectomy which can result in incomplete vitreoretinal ...
Mengyu, Zhang, Youxin, Chen
openaire   +1 more source

Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin

Ophthalmic Surgery, Lasers and Imaging Retina, 2015
Two consecutive cases of symptomatic vitreomacular adhesion with macular hole were treated with intravitreal ocriplasmin. Both were complicated by long-term visual symptoms and chronic serous foveal detachments lasting 17 months post-treatment. These findings suggest direct and long-lasting effects of ocriplasmin on the retinal pigment epithelium and ...
openaire   +2 more sources

Ocriplasmin cost effective in symptomatic vitreomacular adhesion

PharmacoEconomics & Outcomes News, 2020
openaire   +1 more source

What are the effects of ocriplasmin for people with symptomatic vitreomacular adhesion?

Cochrane Clinical Answers, 2018
Sera Tort, Asaf Achiron
openaire   +1 more source

MCED Blood Test Boosts Cancer Detection in Symptomatic Patients

Ca-A Cancer Journal for Clinicians, 2023
Mike Fillon
exaly  

Intravitreal Gas for Symptomatic Vitreomacular Adhesion: A Synthesis of the Literature

Acta Ophthalmologica, 2018
James E Neffendorf, Riti Desai, Timothy Jackson   +2 more
exaly